Zoetis Inc. reported revenue of US$1.25 billion for the fourth quarter of 2013, an increase of 7% from the fourth quarter of 2012, which reflected an operational increase of 9%, with foreign currency having a negative impact of two percentage points.

Net income for the fourth quarter of 2013 was US$105 million, or US$0.21 per diluted share. Adjusted net income for the fourth quarter of 2013 was US$180 million, or US$0.36 per diluted share.

For full year 2013, the company reported revenue of US$4.56 billion, an increase of 5% from the full year 2012, and reflected an operational increase of 7%, with foreign currency having a negative impact of two percentage points.

In 2013, net income was US$504 million, or US$1.01 per diluted share, an increase of 16% compared to the full year 2012. Adjusted net income for the full year 2013 was US$709 million, or US$1.42 per diluted share, an increase of 32% and 31%, respectively, compared to the adjusted full year 2012.

Zoetis Chief Executive Officer Juan Ramón Alaix said, "Our performance in 2013, together with our guidance for 2014, confirms our long-term objective to grow revenue in line with, or faster than, the market; to grow adjusted net income faster than revenue; and to bring additional value to our customers, colleagues and shareholders."

The company continues to expand its diverse portfolio, receiving approvals and bringing important new products to the customers, such as Apoquel for veterinarians in the US, EU and New Zealand, said Alaix.

Zoetis organises and manages its business across four regional operating segments: the US; Europe/Africa/Middle East (EuAfME); Canada/Latin America (CLAR); and Asia/Pacific (APAC). Within each of these regional segments, the company delivers a diverse portfolio of products for livestock and companion animals tailored to local trends and customer needs.

Zoetis continues to drive demand and strengthen its diverse portfolio of products through brand lifecycle management, strong customer relationships and access to new markets and technologies. The company is focused on improving the performance and delivery of its current product lines; expanding product indications across species; and pursuing approvals across new geographies.